Clinigen Group plc, the global pharmaceutical and services company, has partnered with Eisai Europe Ltd to obtain the marketing authorisation and subsequently launch Halaven (eribulin), Fycompa (perampanel) and Lenvima (lenvatinib) into 10 African countries
The new agreement follows the launch of Halaven and Fycompa in South Africa in February and July 2017 respectively.
All three medicines will be submitted for registration in Namibia, Botswana, Zimbabwe, Zambia, Ghana, Nigeria, Kenya, Uganda and Tanzania, subject to local regulatory approval.
Eribulin is currently licensed in South Africa only for the treatment of women with locally advanced or metastatic breast cancer and who have received at least two chemotherapeutic regimens for their disease.
In 2012, breast cancer was the leading cancer among the female population in the majority of countries in Africa and is responsible for one in four diagnosed cancers and one in five cancer deaths in women worldwide.
Perampanel is currently licensed in South Africa for the adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Across Africa, the prevalence of epilepsy varies between 2.2 to 58 cases per 1000 people, with an average prevalence of 15.8 per 1000. The World Health Organisation estimates that in Africa, epilepsy directly affects 10mn people.
Benjamin Miny, managing director of Clinigen for South Africa, said, “This agreement builds on the strong partnership we have with Eisai in providing access to medicines.”
“We are able to leverage our distribution network in the region and local expertise to enable access to these important medicines, helping to address the unmet medical needs of patients and their families across southern Africa,” Miny added.
